Celltrion's manufacturing ops figure in AstraZeneca buyout buzz

A multinational pharma company may have more reason for wanting Celltrion than its biosimilar of multibillion-dollar blockbuster arthritis treatment Remicade. Rumors are swirling that AstraZeneca ($AZN) may have its sights set on the Korean biosimilars maker, and a buyout would give the British drugmaker--or any of its rivals--an established biologics plant in a strategic location, and one that's expanding, at that. Story

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.